India's Serum Institute resumes vaccine exports to COVAX
The Serum Institute of India, the world’s largest vaccine maker, has resumed exports of coronavirus vaccines to the U.N.-backed COVAX distribution program after halting most overseas sales in March
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.The Serum Institute of India the world's largest vaccine maker, resumed exports of coronavirus vaccines to the U.N.-backed COVAX distribution program on Friday after halting most overseas sales in March.
The company was to have been COVAX's main supplier, but an explosion of cases in India resulted in a cutoff of exports. At the time, Serum Institute had contracts to provide COVAX with 200 million doses of AstraZeneca vaccines, and unfinalized agreements to supply 350 million more. The suspension was a significant setback for global efforts to distribute vaccines equitably.
GAVI, the vaccine alliance which co-manages the COVAX program, said the company had provided just under 30 million doses to it.
New infections in India have now fallen to the lowest level in months, and the first new exports under the COVAX program, destined for Nepal and Tajikistan are leaving Friday evening, Serum Institute said in a statement. It said it expects exports to increase substantially in early 2022.
It said it has already produced more than a billion doses of the AstraZeneca vaccine under license, almost all for domestic use.
Serum Institute also started making the Novavax vaccine under license in June. Experts say the vaccine — which has been greenlit by regulators in Indonesia and the Philippines — is easier to store and transport than some others, and this may allow it to play an important role in boosting global vaccine supplies.
With the addition of the new vaccine, “We can be more hopeful that WHO’s target to vaccine 70% of the world’s population by the middle of the next year can be met,” Serum Institute chief executive Adar Poonawalla said,
Although coronavirus restrictions have been lifted in India, the country, like others, is jittery after the detection of a new, worrisome variant in southern Africa. The federal government has asked states to scale up screening of travelers from some countries and the genetic sequencing of any detected infections.
___
Associated Press writer Jamey Keaten in Geneva contributed to this report.
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.